• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neuralgia - Pipeline Review, H2 2012 Product Image

Neuralgia - Pipeline Review, H2 2012

  • Published: November 2012
  • 147 pages
  • Global Markets Direct

Neuralgia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Neuralgia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuralgia. Neuralgia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuralgia.
- A review of the Neuralgia products under development by companies and universities/research institutes based on information derived from company and READ MORE >

2
List of Tables 8
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Neuralgia Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Neuralgia 12
Neuralgia Therapeutics under Development by Companies 14
Neuralgia Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Neuralgia Therapeutics – Products under Development by Companies 24
Neuralgia Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Neuralgia Therapeutics Development 26
Bristol-Myers Squibb Company 26
DURECT Corporation 27
Kyowa Hakko Kirin Co., Ltd. 28
Abbott Laboratories 29
Allergan, Inc. 30
Sanofi-Aventis 31
Daewoong Pharmaceutical Co., Ltd. 32
Pfizer Inc. 33
Merck KGaA 34
EpiCept Corporation 35
AVANIR Pharmaceuticals 36
NeurogesX, Inc. 37
Diamyd Medical AB 38
Proximagen Neuroscience plc. 39
Xenon Pharmaceuticals Inc. 40
Arcion Therapeutics, Inc. 41
KYORIN Pharmaceutical Co., Ltd. 42
Winston Pharmaceuticals, Inc. 43
SantoSolve AS 44
Bial - Portela & Ca, S.A. 45
Spinifex Pharmaceuticals Pty Limited 46
TheraQuest Biosciences, LLC 47
Celtic Pharmaceutical Holdings L.P. 48
Neuralgia – Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
pregabalin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NG2-GAD - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
bupivacaine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ibudilast - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NGX-1998 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AmiKet - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
zucapsaicin reformulation - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
XEN-402 Topical - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SKL-NP - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
zucapsaicin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BVT-115959 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GRT-6005 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Cannabis - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
capsaicin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
duloxetine hydrochloride - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SAR-292833 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
AGN-214868 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
nabilone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
plasmid vascular endothelial growth factor - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ABT-652 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
DWP-05195 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
strontium chloride hexahydrate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
XPF-002 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Varicella-zoster vaccine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Nuedexta - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
EMA-401 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
F-0434 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
KHK-6188 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
mepivacaine hydrochloride - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
BMS-954561 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
minocycline - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Atx-08-001 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
eslicarbazepine acetate - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
ABT-639 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
lidocaine - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
methadone hydrochloride - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
tebanicline tosylate - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
flupirtine maleate - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
NRT-20 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
sulfasalazine - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
d-Methadone - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Neuralgia Therapeutics – Drug Profile Updates 113
Neuralgia Therapeutics – Discontinued Products 136
Neuralgia Therapeutics - Dormant Products 137
Neuralgia – Product Development Milestones 139
Featured News & Press Releases 139
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 139
Oct 17, 2012: Cebix Announces Positive Results Of Ersatta Phase I/II Trial Targeting Peripheral Neuropathy In Type 1 Diabetics 139
Aug 30, 2012: NeurogesX's Partner Astellas Presents Multiple Posters On Qutenza At 14th World Congress On Pain 140
Aug 30, 2012: NeurogesX Presents Phase II Study Data Of NGX-1998 At 14th World Congress on Pain 140
Aug 29, 2012: Janssen Receives FDA Approval For Nucynta Extended-release Oral Tablets For Management Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy 141
Aug 28, 2012: Spinifex Pharma Announces Positive Phase II Results For EMA401 In Postherpetic Neuralgia 142
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147

List of Tables
Number of Products Under Development for Neuralgia, H2 2012 12
Products under Development for Neuralgia – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Development by Companies, H2 2012 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 25
Bristol-Myers Squibb Company, H2 2012 26
DURECT Corporation, H2 2012 27
Kyowa Hakko Kirin Co., Ltd., H2 2012 28
Abbott Laboratories, H2 2012 29
Allergan, Inc., H2 2012 30
Sanofi-Aventis, H2 2012 31
Daewoong Pharmaceutical Co., Ltd., H2 2012 32
Pfizer Inc., H2 2012 33
Merck KGaA, H2 2012 34
EpiCept Corporation, H2 2012 35
AVANIR Pharmaceuticals, H2 2012 36
NeurogesX, Inc., H2 2012 37
Diamyd Medical AB, H2 2012 38
Proximagen Neuroscience plc., H2 2012 39
Xenon Pharmaceuticals Inc., H2 2012 40
Arcion Therapeutics, Inc., H2 2012 41
KYORIN Pharmaceutical Co., Ltd., H2 2012 42
Winston Pharmaceuticals, Inc., H2 2012 43
SantoSolve AS, H2 2012 44
Bial - Portela & Ca, S.A., H2 2012 45
Spinifex Pharmaceuticals Pty Limited, H2 2012 46
TheraQuest Biosciences, LLC, H2 2012 47
Celtic Pharmaceutical Holdings L.P., H2 2012 48
Assessment by Monotherapy Products, H2 2012 49
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Stage and Molecule Type, H2 2012 53
Neuralgia Therapeutics – Drug Profile Updates 113
Neuralgia Therapeutics – Discontinued Products 136
Neuralgia Therapeutics – Dormant Products 137

List of Figures
Number of Products under Development for Neuralgia, H2 2012 12
Products under Development for Neuralgia – Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 18
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Discovery and Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 49
Assessment by Route of Administration, H2 2012 50
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Molecule Type, H2 2012 52
Assessment by Stage and Molecule Type, H2 2012 53

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos